BASF's Agribusiness Carve-Out Nears the Finish Line as Investors Weigh a Two-Track Strategy
Published on 08/23/2026 at 13:12 | Redaktion boerse-global.de
The legal groundwork for BASF's planned separation of its agricultural solutions business is essentially complete across Europe and the Americas, according to board member Livio Tedeschi. That clears the runway for the next phase: readying Agriculture Solutions for a stock market debut targeted for 2027, with an index listing in mind.
The disclosure helped extend a three-session winning streak for the shares in Xetra trading between August 19 and 21. By Friday's close, the stock stood at €51.60, up 0.5 percent on the day and 16 percent higher since the start of the year.
A Spin-Off That Could Reshape the Parent's Valuation
Market observers have floated a valuation range of €20 billion to €30 billion for the agribusiness arm, based on an assessment published August 12. Measured against BASF's current market capitalization of €45.54 billion, that would represent roughly two-thirds of the group's present worth — a striking illustration of the division's heft within the conglomerate and the potential re-rating implications for the chemicals operations left behind.
The timetable remains deliberately open-ended: the IPO is slated for 2027, but no specific window has been confirmed. For shareholders, that leaves a degree of uncertainty over the final structure and timing, even as the legal spadework is now largely done.
Operational Momentum Continues Alongside the Restructuring
The carve-out is far from the only moving part. BASF this week inaugurated a new performance laboratory for diapers and superabsorbents in Mumbai, aimed at strengthening technical application support across the Asia-Pacific region. A low double-digit million-euro investment is also flowing into a new "Climate Center" in Limburgerhof, which will conduct ecotoxicological studies to support global product registrations and is slated for completion in the first half of 2027.
In personal care, the group began marketing the UV filter Bemotrizinol — sold under the brand name Tinosorb S — in the United States in early August, following approval from the US Food and Drug Administration. BASF holds co-exclusive rights under an existing licensing arrangement with DSM Nutritional Products.
There are also signs of pricing power returning in specialty chemicals. The company has lifted European prices for neopentyl glycol and 1,6-hexanediol by €250 and €300 per tonne respectively, with further increases in the US and Canada taking effect September 1. That pricing discipline, combined with a raised full-year guidance for EBITDA before special items of €6.9 billion to €7.7 billion, paints a picture of a group emerging from its trough.
Buybacks and Capital Allocation Under the Microscope
The capital returns program continues in parallel. Between August 10 and 14, BASF repurchased roughly 695,000 of its own shares for about €35.42 million, part of a broader buyback effort that was extended last Thursday with a new tranche of up to €1.0 billion, due to run through the end of April 2027.
As BASF navigates complex regulatory and operational changes, companies across the UK face their own compliance pressures — particularly around workplace safety documentation. Many employers unknowingly miss critical risk-assessment requirements, leaving themselves exposed. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards properly and stay compliant. Download the free Risk Assessment Toolkit
That ongoing repurchase activity sits alongside a longer-term commitment to return €12 billion to shareholders by 2028. The competing claims on capital are worth watching: significant sums are also being directed toward infrastructure, including over €100 million for expanding rail logistics at the Ludwigshafen site.
Two Scenarios, One Question
The bull case rests on the combination of operational recovery and structural simplification. A successfully executed IPO would give the market a separately valued, research-intensive agribusiness player while freeing up capital and management attention for the core chemicals business. Technical indicators support the constructive view: the shares trade roughly 4.8 percent above their 50-day moving average, and about 6.4 percent above the 200-day average of €48.48.
The bear case centers on complexity and timing. An agribusiness IPO is a multi-year undertaking fraught with regulatory, balance-sheet and market uncertainties — progress on preparation is not a commitment to a specific date or valuation. The capital tied up in logistics and climate projects competes directly with the promised shareholder distributions, and any operational stumble in the agribusiness division or delay in the IPO process could trigger a de-rating. The stock's 6.3 percent gap below its 52-week high suggests investors are not yet pricing in euphoria.
The next concrete test arrives October 28, when BASF reports third-quarter results. That update should reveal whether the raised annual guidance holds up and whether the spin-off narrative gains more tangible detail. For now, the market appears willing to give management the benefit of the doubt — but the clock is ticking on delivery.
